SEC Form 4 · accession 0001739515-26-000011
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dietmar Berger
Officer — Chief Medical Officer
Period of report
Sep 10, 2026
Accepted (ET)
Sep 11, 2026 · 6:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 10, 2026 | M | 533 | — | A | 19,785 | D | |
| Common Stock | Sep 10, 2026 | F | 263 | $144.81 | D | 19,522 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Sep 10, 2026 | M | 533 | D | — | — | Common Stock | 533 | 46,395 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- F2The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.